OmniAb Inc
OABI1.637USD
+0.016+1.02%
交易中 （美东）报价延迟15分钟
200.80M总市值
亏损市盈率 TTM
关于 OmniAb Inc 公司
OmniAb, Inc. 提供的发现平台为制药行业合作伙伴提供多种抗体库和高通量筛选技术，从而发现下一代疗法。OmniAb 平台是转基因动物的生物智能 (BI)，包括 OmniRat、OmniChicken 和 OmniMouse，这些动物经过基因改造，可产生具有人类序列的抗体，以促进人类治疗候选药物的开发。该公司的 OmniFlic（转基因大鼠）和 OmniClic（转基因鸡）通过通用轻链方法满足行业对双特异性抗体应用的需求，而 OmniTaur 具有针对复杂靶标的牛抗体的结构属性。该公司的 OmniChicken 和 OmniClic 在进化上遥远的鸡宿主环境中提供亲和力成熟的抗体，可将多种抗体组库递送至保守的治疗靶抗原。
公司简介
公司代码OABI
公司名称OmniAb Inc
上市日期Oct 09, 2020
CEOMr. Matthew William (Matt) Foehr
员工数量114
证券类型Ordinary Share
年结日Oct 09
公司地址5980 Horton Street
城市EMERYVILLE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94608
电话15102507800
网址https://www.omniab.com/
公司代码OABI
上市日期Oct 09, 2020
CEOMr. Matthew William (Matt) Foehr
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
75.54K
+36.01%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
58.33K
+52.17%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
75.54K
+36.01%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
58.33K
+52.17%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
License and milestone revenue
2.02M
48.65%
Service revenue
1.95M
46.82%
Royalty revenue
188.00K
4.53%
暂无数据
业务
地区
业务USD
名称
营收
占比
License and milestone revenue
2.02M
48.65%
Service revenue
1.95M
46.82%
Royalty revenue
188.00K
4.53%
股东统计
更新时间: 9月8日 周一
更新时间: 9月8日 周一
持股股东
股东类型
持股股东
持股股东
占比
Avista Capital Holdings, LP
12.89%
Whitefort Capital Management, LP
8.35%
Ash X LP
6.74%
BlackRock Institutional Trust Company, N.A.
5.16%
The Vanguard Group, Inc.
4.29%
其他
62.57%
持股股东
持股股东
占比
Avista Capital Holdings, LP
12.89%
Whitefort Capital Management, LP
8.35%
Ash X LP
6.74%
BlackRock Institutional Trust Company, N.A.
5.16%
The Vanguard Group, Inc.
4.29%
其他
62.57%
股东类型
持股股东
占比
Investment Advisor
16.49%
Hedge Fund
14.30%
Investment Advisor/Hedge Fund
12.94%
Private Equity
12.89%
Corporation
8.21%
Individual Investor
6.67%
Research Firm
1.02%
Pension Fund
0.14%
Venture Capital
0.11%
其他
27.24%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
348
92.68M
75.53%
-5.84M
2025Q1
359
87.33M
71.43%
-8.58M
2024Q4
365
89.85M
74.79%
-8.38M
2024Q3
394
90.25M
75.21%
-25.05M
2024Q2
389
89.07M
76.08%
-29.09M
2024Q1
378
93.24M
79.93%
-23.55M
2023Q4
374
92.06M
79.14%
-28.03M
2023Q3
352
92.71M
80.23%
-26.22M
2023Q2
337
91.30M
79.07%
-24.17M
2023Q1
319
89.47M
77.82%
-24.53M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Avista Capital Holdings, LP
15.82M
12.93%
--
--
Sep 30, 2024
Whitefort Capital Management, LP
7.31M
5.98%
+3.40M
+86.81%
May 30, 2025
Ash X LP
1.09M
0.89%
+1.09M
--
Jun 12, 2025
BlackRock Institutional Trust Company, N.A.
6.46M
5.28%
+62.83K
+0.98%
Mar 31, 2025
The Vanguard Group, Inc.
5.18M
4.23%
+142.26K
+2.82%
Mar 31, 2025
Foehr (Matthew W)
3.80M
3.1%
-13.61K
-0.36%
Apr 23, 2025
Dimensional Fund Advisors, L.P.
3.13M
2.56%
+106.04K
+3.50%
Mar 31, 2025
Higgins (John L)
2.85M
2.33%
+20.00K
+0.71%
Jun 17, 2025
Rice Hall James & Associates, LLC
2.58M
2.11%
-68.23K
-2.58%
Mar 31, 2025
Private Management Group, Inc.
2.53M
2.07%
+296.71K
+13.29%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
iShares Morningstar Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
Dimensional US Core Equity 1 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
WisdomTree US SmallCap Fund
0%
iShares Genomics Immunology and Healthcare ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Fidelity Small-Mid Multifactor ETF
0%
Global X Russell 2000 Covered Call ETF
0%
查看更多
iShares Morningstar Small-Cap ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
iShares Morningstar Small-Cap Value ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
Fidelity Nasdaq Composite Index ETF
占比0%
WisdomTree US SmallCap Fund
占比0%
iShares Genomics Immunology and Healthcare ETF
占比0%
Fidelity MSCI Health Care Index ETF
占比0%
Fidelity Small-Mid Multifactor ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
